229. 肺胞蛋白症(自己免疫性又は先天性) Autoimmune pulmonary alveolar proteinosis Clinical trials / Disease details


臨床試験数 : 43 薬物数 : 34 - (DrugBank : 8) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 14

  
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03006146
(ClinicalTrials.gov)
July 13, 201728/11/2016Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar ProteinosisEvaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar ProteinosisAutoimmune Pulmonary Alveolar ProteinosisDrug: SargramostimChildren's Hospital Medical Center, CincinnatiRare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS)Completed18 Years80 YearsAll10Phase 1United States
2NCT02835742
(ClinicalTrials.gov)
September 1, 201613/7/2016Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in JapanPulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in JapanPulmonary Alveolar Proteinosis, AutoimmuneDrug: Sargramostim;Drug: PlaceboNiigata University Medical & Dental HospitalNULLCompleted16 Years80 YearsAll78Phase 2Japan
3NCT02840708
(ClinicalTrials.gov)
May 201613/7/2016SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudySK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic StudyPulmonary Alveolar Proteinosis, AutoimmuneDrug: SargramostimNiigata University Medical & Dental HospitalNULLCompleted20 Years80 YearsAll14Phase 1Japan
4NCT00901511
(ClinicalTrials.gov)
July 200911/5/2009Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)Whole Lung Lavage Followed by Inhaled Sargramostim in the Treatment of Autoimmune Pulmonary Alveolar ProteinosisPulmonary Alveolar ProteinosisDrug: GM-CSF [Leukine (Sargramostim)];Procedure: WLLIRCCS Policlinico S. MatteoAgenzia Italiana del FarmacoEnrolling by invitation18 YearsN/ABoth18Phase 2/Phase 3Italy
5EUCTR2008-007086-23-IT
(EUCTR)
12/12/200827/01/2009Whole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAPWhole lung lavage followed by inhaled Sargramostim in the treatment of autoimmune pulmonary alveolar proteinosis. - WLL/inhaled GM-CSF in autoimmune PAP Autoimmune PAP
MedDRA version: 9.1;Level: LLT;Classification code 10037316;Term: Pulmonary alveolar proteinosis
Trade Name: Leukine
INN or Proposed INN: Sargramostim
OSPEDALE POLICLINICO S. MATTEONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
6NCT00030056
(ClinicalTrials.gov)
September 200130/1/2002GM-CSF in Patients With Pulmonary Alveolar ProteinosisTrial of GM-CSF for Alveolar ProteinosisPulmonary Alveolar ProteinosisDrug: GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)The Cleveland ClinicNULLTerminated18 Years70 YearsBoth48Phase 2United States